# Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

> **NCT04456452** · PHASE1 · COMPLETED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 10 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Ampion
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04456452
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2020-09-08
- **Final completion:** 2020-11-30
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456452, "Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04456452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*